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H· EREDITARY TYROSINEMIA is a metabolic disor-der characterized by deficiency of the enzyme fum-
marylacetoacetate, resulting in the accumulation of tyrosine 
metabolites, which are toxic to the liver. Hepatic dysfunc-
tion, associated with tyrosinemia, varies from an acute form 
of liver failure to a chronic, progressive form that leads to 
cirrhosis and hepatocellular carcinoma (HCC).1.2 
Liver transplantation is the treatment of choice for end-
stage hepatic disease brought about by several metabolic 
disorders, including tyrosinemia. Liver replacement has also 
been offered to patients with primary hepatic malignancies.) 
Despite the fact that liver transplantation cU\:eS the underly-
ing metabolic defect in patients with tyrosinemia: little is 
known about the proper timing for transplantation in such 
(Table 1). One patient died of recurrence of malignant 
disease five months following transplantation, with wide-
spread metastases involving the hepatic allograft, lungs, 
bones, and brain. This patient had HCC involving the right 
lobe, with invasion of the portal and hepatic veins. The other 
four patients are alive and free of recurrence (median 56, 
ranging from 42 to 78 months). At the time of the last 
follow-up, these four patients had normal liver function tests. 
Three are performing well at school, and one is working full 
time. 
All five patients with HCC were older than two years of 
age. Three of the 10 patients were under two years of age, 
and although their excised livers showed severe dysplasia, 
none had HCC. Nine patients had markedly elevated alpha-
Table 1. Clinical Features of Five Liver Transplant Recipients for Tyrosinemia and HCC 
Case Age at Indication Survival 
No. Oll (yr) for Oll location (mo) Follow-up 
1 23/, Hepatoma Both lobes 78 School, normal LFTs 
2 21 Liver failure Right lobe 56 Working, normal LFTs 
p resection for HCC 
3 3'1. Cirrhosis + Both lobes 48 School, normal LFTs 
suspected hepatoma 
4 3 Cirrhosis Both lobes 42 School, normal LFTs 
5 5"1,. Hepatoma Right lobe 5 Recurrence 
Note: HCC - Hepatocellular carcinoma; OL T - OrthotopiC liver transplantation; LFTs - Liver function tests 
patients and the potential consequences of replacing the liver 
in the presence of HCC. 
The purpose of this investigation is to reportour experi-
ence with hepatic transplantation for tyrosinemia in the 
presence of HCC. 
PATIENTS AND METHODS 
Between March 1980and December 1987.1043 patients underwent 
liver transplantation at the University of Pittsburgh. Ten patients 
received 11 liver transplants for tyrosinemia. Nine were children 
(less than 18 years of age), and one was a 21-year-old adult. The 
records of these 10 patients were carefully reviewed. and the 
following information was obtained: demographic data, biochemi-
cal/histologic analysis for tyrosinemia. location of tumor. vascular 
invasion, recurrence, and survival in months. Liver function tests and 
the patient's quality of life at the time of last follow-up were also 
recorded. In each case, a diagnosis of tyrosinemia was made based on 
the clinical findings. the presence of elevated plasma and urine 
tyrosine, phenylalanine, and methionine, and the presence of succi-
nylacetone in the urine. 
RESULTS 
Five of the 10 patients had HCC at the time of transplanta-
tion, with follow-up ranging from five months to 78 months 
fetoprotein. This information was not available in one 
patient. 
DISCUSSION 
Liver transplantation is an effective mode of therapy for 
patients with liver disease secondary to inborn errors of the 
metabolism. but the result's have been disappointing when 
the indication for transplantation is HCC due to the high 
recurrence rate. 5•6 Most of the recurrences seem to occur 
within the first year following transplantation. On the other 
hand, the recurrence rate is almost nonexistent in patients 
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with HCC in whom the main indication for transplantation is 
an underlying nonmalignant liver disease, such as cirrhosis.' 
This is probably the result of tumor involvement, since in the 
former group, the tumor is usually so extensive that a 
conventional subtotal hepatectomy is not possible, whereas in 
the latter group, resection of the tumor would be possible, if 
the underlying liver parenchyma was normal. However, in 
the present study, the extent of tumor involvement of the 
liver did not seem to have any prognostic significance, since 
four patients with bilateral involvement of the liver have had 
no evidence of recurrence thus far. 
Interestingly, the patient with tumor confined to the right 
lobe of the liver died of recurrence shortly after transplanta-
tion. Unlike the other cases, this particular patient had 
extensive invasion of the portal and hepatic veins. 
The proper timing for hepatic replacement in patients with 
tyrosinemia is a topic of confusion among pediatricians and 
surgeons. Careful consideration should be given to patients 
older than two years of age, since the incidence of HCC 
increases considerably beyond that age.' The follow-up on 
these patients is particularly difficult, since the alphafetopro-
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tein is usually elevated and the presence of nodules makes it 
difficult for the radiologist to distinguish between a benign 
regenerative nodule and malignancy. 
In conclusion, the presence of hepatocellular carcinoma 
and cirrhosis due to hereditary tyrosinemia is not a contrain-
dication for liver transplantation. 
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